RXRX earnings date and last-quarter result: last quarter miss, P/E -2.48. Updated 2026-07-23.
Recursion Pharmaceuticals (RXRX) Research Hub
Recursion Pharmaceuticals (RXRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.8 USD (+2.70%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.48, market cap 1.34B. This hub links to the full technical, earnings and options research available for RXRX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.8 USD (+2.70%) |
| 52-week range | 2.84 USD – 5.19 USD |
| Trend regime | Range |
| 14-day RSI | 37.5 (Bearish) |
| Trailing P/E | -2.48 |
| Market cap | 1.34B |
| Dividend yield | 0.00% |
Available research for RXRX
Covered Call on RXRX: how it works, illustrative setup around the real 3.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RXRX: how it works, illustrative setup around the real 3.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RXRX: how it works, illustrative setup around the real 3.8 USD price, max profit/loss, breakeven and when to use it. Educational.
RXRX technical analysis: range, last 3.8 USD, RSI 37.5, 52w range 2.84 USD–5.19 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RXRX in?
Recursion Pharmaceuticals (RXRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RXRX in an uptrend or downtrend?
As of 2026-10-26, RXRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RXRX's trailing P/E ratio?
RXRX's trailing P/E is -2.48, with a market cap of 1.34B. See the earnings research page for full valuation detail.